Can this covid-times saviour navigate the self-inflicted deep slump?
The all-or-nothing strategy has landed the ‘pride of the pharmaceutical industry' in a situation that deteriorated rapidly.
Novavax's quarterly loss shrinks as it ramps down spending on COVID vaccines
Novavax's fourth-quarter loss narrowed on Thursday, helped by reduced selling and administrative expenses of COVID-19 ...
RFK Jr. pauses Peninsula company's oral Covid vaccine clinical trial
A recent modification to the contract would have allowed Vaxart to invoice BARDA for the remaining $230 million or so for ...
pulmonologyadvisor23h
COVID-19 Omicron Era: Immunocompromised Benefited From Tixagevimab-Cilgavimab
Tixagevimab-cilgavimab reduced risk for severe COVID-19 progression in patients with hematologic malignancies on anti-CD20 therapy during the early Omicron era.
Zacks Research Issues Positive Forecast for Pfizer Earnings
Equities researchers at Zacks Research raised their Q3 2025 earnings estimates for Pfizer in a report issued on Monday, February 24th. Zacks Research analyst K. Shah now forecasts that the ...